It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of SpectrumDNA, Inc. (“SPXA” or “the Company”) (CIK No. 0001424988) because of concerns about the adequacy and accuracy of publicly available information concerning SPXA, including its financial condition and its operations, if any, in light of the absence of any public disclosure by the company since 2015, and because of concerns about investors confusing this issuer with a similarly-named private company that is a manufacturer of saliva collection devices and the subject of increased media attention during the ongoing COVID-19 pandemic. SPXA is a Delaware corporation that reported in 2015 having its principal place of business located in Spokane, Washington. The Company’s common stock is quoted on OTC Link (previously “Pink Sheets”), operated by OTC Markets Group, Inc., under the symbol SPXA, has 8 market makers and is eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.
THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EDT on April 22, 2020 through 11:59 p.m. EDT on May 5, 2020.

By the Commission.

Vanessa A. Countryman
Secretary